A Phase IIa study to evaluate the safety, tolerability, and effects of AZP-531 on food-related behavior in patients with Prader-Willi Syndrome

Registry ID

EUCTR2014-001670-34

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Alize Pharma

Start date

2015-01-26

Last update

2026-08-16

Conditions

• Prader-Willi Syndrome

Summary

To evaluate the safety and tolerability of one dose of AZP-531 adjusted for bodyweight (2, 3 or 4 mg) administered over 2 weeks as daily subcutaneous injection.

Locations

• , , Spain
• , , Italy
• , , France

Related clinical trials

• Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
• Parent and Infant Inter(X)Action Intervention (PIXI)
• The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics
• Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion Dysregulation
• A Study of CSTI-500 in Patients With Prader-Willi Syndrome
• Impact of Bright Light Therapy on Prader-Willi Syndrome

View on source registry